Multivisceral resection for ovarian cancer with peritoneal carcinomatosis following induction bidirectional chemotherapy using pressurized intraperitoneal aerosol chemotherapy
Open Access
- 7 June 2026
- journal article
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 7 (2) , 86-98
Abstract
Peritoneal carcinomatosis in advanced ovarian cancer is an unfavorable prognostic factor and limits the efficacy of systemic chemotherapy. This provides a rationale for the use of locoregional treatment modalities, including pressurized intraperitoneal aerosol chemotherapy (PIPAC). Of particular interest is the safety of a bidirectional strategy (systemic chemotherapy + PIPAC) in patients requiring multivisceral resection. We present a clinical case of a patient with advanced ovarian cancer and peritoneal carcinomatosis. Induction bidirectional chemotherapy was administered, consisting of paclitaxel/carboplatin (6 cycles) combined with PIPAC using cisplatin 30 mg/m² (50 mg), 30-minute exposure, 3 sessions, followed by multivisceral cytoreductive surgery. Efficacy was assessed based on tumor marker dynamics, peritoneal cancer index (PCI), and morphological response (TRG), while safety was evaluated according to perioperative complications and the feasibility of continuing PIPAC after surgery. At initial laparoscopy in April 2025, peritoneal carcinomatosis was detected (PCI 26); the first PIPAC session was performed, followed by systemic chemotherapy. After the second cycle, a partial response was documented. In June 2025, multivisceral cytoreductive surgery was performed, including anterior resection of the rectum with sigmoid stoma formation. Systemic therapy was resumed early and completed up to 6 cycles. By 20.08.2025, tumor markers had decreased: CA-125 to 47 U/mL, CA 19–9 to 13.7 U/mL, and HE-4 to 120 U/mL. Before PIPAC-2 (September 2025), no macroscopic carcinomato sis was detected (PCI 0); no tumor cells were found in peritoneal biopsy specimens, corresponding to TRG 1. At PIPAC-3 (November 2025), PCI remained 0, and repeat biopsies also corresponded to TRG 1. Induction bidirectional chemotherapy including PIPAC in a patient with advanced ovarian cancer and peritoneal carcinomatosis demonstrated clinical feasibility, safety and marked antitumor efficacy even after multivisceral cytoreduction.Keywords
This publication has 17 references indexed in Scilit:
- ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseAnnals of Oncology, 2024
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialThe Lancet, 2015
- Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysisGynecologic Oncology, 2013
- Description of a novel approach for intraperitoneal drug delivery and the related deviceSurgical Endoscopy, 2012
- Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidenceNature Reviews Clinical Oncology, 2009
- Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysisGynecologic Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal antineoplastic drug delivery: rationale and resultsThe Lancet Oncology, 2003
- Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis1996